Precision Therapy Assessments

Precision Therapy Assessments are comprehensive health technology assessments evaluating therapies, which target genes, proteins, and other molecules, or are guided by molecular testing, such as specialty drugs and gene therapies.

Used in conjunction with our Laboratory Insights database, these reports provide the critical evidence context for the use of genetic tests, including panel tests. These reports include the Hayes Rating to indicate the overall strength and direction of the body of evidence for the precision therapy.

Precision Therapy Assessments provide evidence-based support for the development of coverage policy, utilization management, and evidence-based clinical practices. Reports are reviewed annually up to 5 years post publication to determine if there is new literature or evidence that would impact a change in rating and warrant an updated report.

Teduglutide (Gattex; Shire-NPS Pharmaceuticals Inc.) to Reduce Parenteral Support Requirements in Adults with Short Bowel Syndrome

Health Problem: Short bowel syndrome (SBS) is a rare malabsorptive condition in which the bowel is anatomically or functionally inadequate to meet absorptive nutritional needs. The goal of SBS therapy is to optimize enteral autonomy and reductions in parenteral support (PS) requirements, which is associated with morbidity, complications, redu…

Adoptive Immunotherapy Using Genetically Modified Lymphocytes for Lymphoproliferative Disorders and Hematological Malignancies

Rationale: CAR T cells and genetically engineered TCR T cells are targeted, personalized therapies for malignancies and other neoplastic disorders, including hematological cancers and lymphoproliferative diseases. Although alternative treatments, including chemotherapy, radiation, monoclonal antibodies, hematopoietic stem cell transplants (HS…

Sofosbuvir-Velpatasvir for Chronic HCV Infection

Purpose of Technology: Sofosbuvir-velpatasvir (Epclusa) is a “next-generation” once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir.